meta-Iodobenzylguanidine, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents neointimal hyperplasia

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 3, 2008, Pages 717-724

  Yau, Lorraine ^a,b   Molnar, Peter ^a,b   Moon, Michael C ^a,b   Buhay, Shelly ^b   Werner, Jeffrey P ^a,b   Molnar, Katerina ^b   Saward, Laura ^b   Del Rizzo, Dario ^a,b   Zahradka, Peter ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^c St Boniface Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 3 AMINOBENZAMIDE; ARGININE; FIBRIN GLUE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PD 128763; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFICACY; DRUG RELEASE; HISTOPATHOLOGY; IN VIVO STUDY; MORPHOMETRICS; NONHUMAN; ORGAN CULTURE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; RESTENOSIS; SINGLE DRUG DOSE; SWINE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; HYPERPLASIA; INTIMA; MALE; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; PIG;

3-IODOBENZYLGUANIDINE; ADP RIBOSE TRANSFERASES; ANIMALS; ARGININE; ENZYME INHIBITORS; HYPERPLASIA; MALE; ORGAN CULTURE TECHNIQUES; SWINE; TUNICA INTIMA;

EID: 53849098583     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137513     Document Type: Article

References (40)

1. Andrés V and Castro C (2003) Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol 1:85-98.
2. Beller CJ, Radovits T, Kosse J, Gerö D, Szabó C, and Szabó G (2006) Activation of the peroxynitrite-poly(adenosine diphosphate-ribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterectomy. J Vasc Surg 43:824-830.
3. Biasucci LM, Liuzzo G, Buffon A, and Maseri A (1999) The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol 4:105-110.
4. Corda D and Di Girolamo M (2003) Functional aspects of protein mono-ADP-ribosylation. EMBO J 22:1953-1958.
5. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667-678.
6. Del Rizzo DF, Yurkova N, Moon MC, Litchie B, and Zahradka P (2002) Platelet-derived growth factor-induced expression of c-fos in human vascular smooth muscle cells: implications for long-term graft patency. Ann Thorac Surg 74:90-95.
7. Di Girolamo M, Dani N, Stilla A, and Corda D (2005) Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. FEBS J 272:4565-4575.
8. Douglas JS Jr (2007) Pharmacologic approaches to restenosis prevention. Am J Cardiol 100:10K-16K.
9. Ekelund S, Nygren P, and Larsson R (2001) Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem Pharmacol 61:1183-1193.
10. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, Strazdins U, and Saltups A (2007) A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 50:491-497.
11. García-García HM, Vaina S, Tsuchida K, and Serruys PW (2006) Drug-eluting stents. Arch Cardiol Mex 76:297-319.
12. Hauschildt S, Ulmer AJ, Flad HD, Heyden T, and Heine H (1998) ADP-ribosylation: role in LPS-induced phosphorylation of two cytosolic proteins (p36/38) in monocytes. Prog Clin Biol Res 397:147-155.
13. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, and Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202.
14. JónssonO, Halldórsson H, Kjeld M, and Thorgeirsson G (1998) Inhibitory effects of meta-iodo-benzylguanidine (MIBG) on endothelial histamine receptor binding. Biochim Biophys Acta 1379:143-150.
15. Karshovska E, Zernecke A, Sevilmis G, Millet A, Hristov M, Cohen CD, Schmid H, Krotz F, Sohn HY, Klauss V, et al. (2007) Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 27:2540-2547.
16. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, et al. (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030-1039.
17. Miller EG (1975) Stimulation of nuclear poly (adenosine diphosphate-ribose) polymerase activity from HeLa cells by endonucleases. Biochim Biophys Acta 395:191-200.
18. Moon MC, Molnar K, Yau L, and Zahradka P (2004) Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. J Vasc Surg 40:130-137.
19. Moon MC, Yau L, Wright B, and Zahradka P (2008) Injury-induced expression of cytokeratins 8 and 18 by vascular smooth muscle cells requires concurrent activation of cytoskeletal and growth factor receptors. Can J Physiol Pharmacol 86:223-231.
20. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323.
21. Perin EC (2005) Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. Rev Cardiovasc Med 6 (Suppl 1):S13-S21.
22. Plaschke K, Kopitz J, Weigand MA, Martin E, and Bardenheuer HJ (2000) The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia. Neurosci Lett 284:109-112.
23. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, and Ozaki CK (2000) Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102:1697-1702.
24. SchömigA, Kastrati A, and Wessely R (2005) Prevention of restenosis by systemic drug therapy: back to the future? Circulation 112:2759-2761.
25. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, and Zalewski A (1996) Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94:1655-1664.
26. Slavin L, Chhabra A, and Tobis JM (2007) Drug-eluting stents: preventing restenosis. Cardiol Rev 15:1-12.
27. Sparidans RW, Taal BG, and Beijnen JH (1999) Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin. J Chromatogr B Biomed Sci Appl 730:193-199.
28. Spaulding C, Daemen J, Boersma E, Cutlip DE, and Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989-997.
29. SzabóC and Dawson VL (1998) Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287-298.
30. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, and Beijnen JH (1996) Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14:1829-1838.
31. Webster MW and Ormiston JA (2007) Drug-eluting stents and late stent thrombosis. Lancet 370:914-915.
32. Weintraub WS (2007) The pathophysiology and burden of restenosis. Am J Cardiol 100:3K-9K.
33. Wilson DP, Saward L, Zahradka P, and Cheung PK (1999) Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 42:761-772.
34. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, et al. (2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297:2001-2009.
35. Yau L, Elliot T, Lalonde C, and Zahradka P (1998) Repression of phosphoenolpyruvate carboxykinase gene activity by insulin is blocked by 3-aminobenzamide but not by PD128763, a selective inhibitor of poly(ADP-ribose) polymerase. Eur J Biochem 253:91-100.
36. Yau L, Litchie B, Thomas S, Storie B, Yurkova N, and Zahradka P (2003) Endogenous mono-ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression. Eur J Biochem 270:101-110.
37. Yau L, Litchie B, and Zahradka P (2004) MIBG, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents differentiation of L6 skeletal myoblasts by inhibiting expression of myogenin and p21(cip1). Exp Cell Res 301:320-330.
38. Yau L and Zahradka P (2004) ADP-ribosylation and the cardiovascular system, in Pathophysiology of Cardiovascular Disease (Dhalla NS, Rupp H, Angel A and Pierce GN eds) pp 361-382, Kluwer Academic Publishers, Boston.
39. Zahradka P and Ebisuzaki K (1982) A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase. Eur J Biochem 127:579-585.
40. Zingarelli B, Cuzzocrea S, Zsengellér Z, Salzman AL, and Szabó C (1997) Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 36:205-215.